As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
|Articles|November 1, 2007
- Volume 0 0
TEVA SETTLES PATENT CHALLENGE OF GSK DRUGS
Advertisement
Teva Pharmaceutical IndustriesLtd has resolved itspatent dispute with GlaxoSmithKline (GSK) via a settlement that will allow the Israel-basedgeneric drug maker to enter the US market with itsgeneric versions of 3 GSK diabetes drugs: Avandia (rosiglitazonemaleate), Avandamet (rosiglitazone maleate and metforminHCl), and Avandaryl (rosiglitazone maleate andglimepiride) oral tablets. Although details of the settlementwere held confidential by both parties, it was disclosed thatTeva could begin US marketing of the GSK drugs late in thefirst quarter of 2012. GSK filed several lawsuits challengingTeva?s plans to market generic versions of its drugs, and atrial in federal court had been scheduled to begin in August.
Articles in this issue
almost 19 years ago
Understanding the Metabolic Syndromealmost 19 years ago
LABOR DEPT SEES SLOWDOWN IN Rx COSTS, THANKS TO GENERICSalmost 19 years ago
can you READ these Rxs?almost 19 years ago
Case Studiesalmost 19 years ago
compounding HOTLINEalmost 19 years ago
HYPERTENSION WATCHalmost 19 years ago
DIABETES WATCHalmost 19 years ago
CHOLESTEROL WATCHalmost 19 years ago
ASTHMA WATCHalmost 19 years ago
ARTHRITIS WATCHAdvertisement
Related to this article
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
4
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
5